<DOC>
	<DOCNO>NCT01045772</DOCNO>
	<brief_summary>This single-center open label study IL-1 transfusion protein rilonacept subject Muckle-Wells syndrome ( MWS ) , Schnitzler syndrome ( SchS ) Germany . Prospective subject recruit patient population previously characterize observational study , referral within German CAPS community ; SchS subject recruit Charité Patient pool . The Baseline phase begin Screening visit ( day -21 = Visit 1 ) continue three week ; DHAFs ( Daily Health Assessment Forms ) collect subject Day - 21 Day 0 . DHAF information include MWAS ( Muckle-Wells Activity Score ) , SCHAS ( Schnitzler Activity Score ) value period use baseline phase evaluation . Inclusion receive rilonacept occur day 0 ( = Visit 2 ) . On day 0 eligible subject receive load dose two subcutaneous ( S.C. ) injection rilonacept total 320 mg . Subsequent study drug injection rilonacept 160 mg administer week four week . After subject complete initial 4-week treatment phase , eligible receive rilonacept 160 mg weekly 48 week extend treatment phase . DHAFs use ass symptom throughout study . Overall max . 12 subject either MWS SchS enrol .</brief_summary>
	<brief_title>Safety Tolerability Rilonacept Muckle-Wells Syndrome ( MWS ) Schnitzler Syndrome ( SchS )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Cryopyrin-Associated Periodic Syndromes</mesh_term>
	<mesh_term>Cellulitis</mesh_term>
	<mesh_term>Eosinophilia</mesh_term>
	<mesh_term>Schnitzler Syndrome</mesh_term>
	<criteria>Adult ( 18 year old ) Symptomatic MWS diagnosis base family history MWS evidence genetic mutation CIAS1 , Symptomatic SchS Able read , understand willing sign inform consent form abide study procedure Able read , understand complete studyrelated questionnaire ( subject must complete diary ≥ 11 21 day prior Visit 2 ) Willing , commit able return clinic visit complete studyrelated procedure , include willingness selfadminister SC injection SC injection administer qualified person In female childbearing potential : Negative pregnancy test ; male female willing use highly effective contraception ( PearlIndex &lt; 1 ) . In men : Willingness utilize highly effective contraception partner [ ] become pregnant full course study All subject receive normal Chest radiograph ( CXR ) within 6 month prior enrollment ( sign consent ) note absence calcify granuloma and/or pleural scar consistent tuberculosis Subjects consider eligible , active tuberculosis rule appropriate measurement ( e.g . PPD skin test , QuantiFERONTB ) Treatment live ( attenuate ) virus vaccine three month prior visit 2 Current recent treatment ( less 5 half life ) TNF inhibitor Concurrent /ongoing treatment Anakinra ( Kineret ) An abnormal chest radiograph consistent clinical sign prior present tuberculosis infection whether previously treat antituberculosis agent A history listeriosis , active tuberculosis , persistent chronic active infection ( ) require treatment parenteral antibiotic , parenteral antiviral , parenteral antifungal within four week , oral antibiotic , oral antiviral , oral antifungal within four week prior Screening visit Significant concomitant illness , limited , cardiac , renal , neurological , endocrinological , metabolic , lymphatic hematological disease would adversely affect subject 's participation evaluation study Active systemic inflammatory condition include , limited , rheumatoid arthritis , systemic lupus erythematosis , polymyalgia rheumatic , vasculitis , myositis History fibromyalgia chronic fatigue syndrome Evidence current HIV , Hepatitis B , Hepatitis C infection clinical serological history History malignancy include malignant hematological disorder successfully treat nonmetastatic cutaneous , basal , squamous cell carcinoma and/or situ cervical cancer within five year Screening visit History demyelinate disease multiple sclerosis Severe respiratory disease , include , limited severe bronchiectasis , chronic obstructive pulmonary disease , bullous lung disease , uncontrolled asthma , pulmonary fibrosis Known hypersensitivity CHO cell derive therapeutic proteins component rilonacept Presence follow laboratory abnormality enrollment visit : creatinine &gt; 1.5 x Upper Limit Normal ( ULN ) , WBC &lt; 3.6 x 103/mm3 ; platelet count &lt; 150,000 mm3 ; ALT AST &gt; 2.0 x ULN Lactating female pregnant female Enrollment another investigational treatment device study use investigational agent , completion le 4 week 5 halflives , whichever longer , since end another investigational device drug trial Subjects concern compliance protocol procedures Any medical condition , opinion Investigator , would interfere participation study place subject risk Present History substance abuse ( drug alcohol ) factor ( e.g. , serious psychiatric condition ) could limit subject 's ability comply study procedure Subjects detain officially legally official institute Deafness Dementia due cerebral amyloidosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Schnitler syndrome , Muckle-Wells syndrome , anti-IL-1</keyword>
</DOC>